Immutep LTD ADR buy tamam
Summary
This prediction ended on 04.06.19 with a price of €0.012. Massive losses of -99.53% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Immutep LTD ADR | -7.194% | -7.194% | 32.308% | -34.518% |
| iShares Core DAX® | -0.530% | 2.858% | 15.472% | 17.034% |
| iShares Nasdaq 100 | -0.580% | 4.871% | 28.534% | 54.277% |
| iShares Nikkei 225® | -1.097% | -1.658% | 7.461% | 3.656% |
| iShares S&P 500 | -0.730% | 2.647% | 24.918% | 45.236% |
Comments by tamam for this prediction
In the thread Immutep LTD ADR diskutieren
Prima Biomed, ¨buy the dips¨
The stock is a former runner that I am very familiar with, having traded it the first time it ran up a few years back.
Data for the company´s LAG-3 candidate may have been somewhat derisked due to validation from much larger competitor Bristol-Myers Squibb.
Their June financing appears to have taken dilution risk off the table, for now.
There are several important catalysts coming up in the near and medium term which could cause history to repeat itself.
There are several important catalysts coming up.
Patient recruitment for the randomized portion of the phase 2 study in metastatic breast cancer should finish up in the first half of 2018, but in the meantime we can expect final safety run in data in the fourth quarter this year. Also, data from the first and second cohorts of the TACTI-mel phase 1 Australian study in metastatic melanoma evaluating IMP321 in combination with Keytruda will be presented prior to year end at major medical conferences. Data from all three cohorts will be
presented in the first half of next year.